Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib

Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib

Abstract Background Cell-free DNA (cfDNA) genotyping in plasma using the cobas EGFR Mutation Test v2 (cobas) is the first liquid biopsy as a companion diagnosis to identify the EGFR T790M mutation (T790M) after the failure of treatment of EGFR-tyrosine kinase inhibitors (TKIs) (1st generation, gefit...

Full description

Bibliographic Details
Main Authors: Yuko Oya, Tatsuya Yoshida, Kazuhiro Asada, Tetsuya Oguri, Naoki Inui, Sayako Morikawa, Kentaro Ito, Tomoki Kimura, Eiji Kunii, Takashi Matsui, Akihito Kubo, Tatsuo Kato, Takashi Abe, Takeshi Tsuda, Toyoaki Hida
Format: Article
Language:English
Published: BMC 2021-01-01
Series:BMC Cancer
Subjects:
Epidermal growth factor receptor (EGFR)
EGFR-tyrosine kinase inhibitor
Non-small cell lung cancer (NSCLC)
Afatinib
Online Access:https://doi.org/10.1186/s12885-020-07777-2

Internet

https://doi.org/10.1186/s12885-020-07777-2

Similar Items